█ ｜By ACB News Stock Market Editorial Team
ASX-listed medical technology company Compumedics Limited (ASX: CMP) announced on November 10 that it has secured a new A$4.9 million magnetoencephalography (MEG) system order from Beijing Normal University, lifting total contracted MEG revenues to about A$25 million. The deal strengthens the company’s leadership in Asia’s fast-growing neuro-imaging market and highlights robust demand from China’s expanding neuroscience sector.
Signed through Compumedics’ long-term Chinese distributor Beijing Fistar, the contract includes an EEG-synchronized recording system and CURRY neuro-imaging software.
Delivery is scheduled for FY27, following three other systems already in production for FY26 shipment. The company will receive an initial deposit this month, with milestone payments upon delivery and installation.
Beijing Normal University selected the Orion LifeSpan™ MEG system after a competitive technical review. Gordon Haid, Compumedics’ Global Neuro-Imaging Director, said the system’s dual-helmet design, 100% helium recycling and CURRY analysis platform were key differentiators.
The company Executive Chairman Dr David Burton described the order as “a milestone in Orion LifeSpan™’s market penetration,” noting it brings total MEG systems sold in China to five.
Compumedics is also preparing to re-enter the North American market in 2026 while expanding in Europe, with MEG expected to serve as a key revenue driver over the coming years.
The Orion LifeSpan™ system maps brain activity using patented DROS SQUID sensors that deliver high precision and near-continuous operation through cryogen recycling.
Founded in 1987 and headquartered in Melbourne, Compumedics develops diagnostic technologies for sleep, brain and blood-flow monitoring, with operations spanning the Americas, Asia-Pacific, Europe and the Middle East.
Disclaimer
The information provided on this website is for general informational purposes only and does not constitute financial or investment advice. While every effort is made to ensure accuracy, we do not guarantee the completeness, reliability, or timeliness of any content. Investment involves risk. Always seek independent, professional advice before making any financial decisions.
